Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

As a new class of antidiabetic drug, incretin-based therapies, which include dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have raised concerns about symptoms of withdrawal in patients with type 2 diabetes mellitus (T2DM), such as dizziness an...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Le, Yu, Shuqing, Cipriani, Andrea, Wu, Shanshan, Huang, Yi, Zhang, Zilu, Yang, Jun, Sun, Yixin, Yang, Zhirong, Chai, Sanbao, Zhang, Yuan, Ji, Linong, Zhan, Siyan, Sun, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JKL International LLC 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844583/
https://www.ncbi.nlm.nih.gov/pubmed/31788342
http://dx.doi.org/10.14336/AD.2019.0303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844583/
https://www.ncbi.nlm.nih.gov/pubmed/31788342
http://dx.doi.org/10.14336/AD.2019.0303

Ejemplares similares